<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T20:07:16Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:5851995" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:5851995</identifier><datestamp>2018-03-21</datestamp><setSpec>scirep</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Sci Rep</journal-id>
      <journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id>
      <journal-title-group>
        <journal-title>Scientific Reports</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2045-2322</issn>
      <publisher>
        <publisher-name>Nature Publishing Group UK</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5851995</article-id>
      <article-id pub-id-type="pmcid">PMC5851995</article-id>
      <article-id pub-id-type="pmc-uid">5851995</article-id>
      <article-id pub-id-type="pmid">29540745</article-id>
      <article-id pub-id-type="publisher-id">22842</article-id>
      <article-id pub-id-type="doi">10.1038/s41598-018-22842-4</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Structural characterisation of the catalytic domain of botulinum neurotoxin X - high activity and unique substrate specificity</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" equal-contrib="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9527-2310</contrib-id>
          <name>
            <surname>Masuyer</surname>
            <given-names>Geoffrey</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Zhang</surname>
            <given-names>Sicai</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Barkho</surname>
            <given-names>Sulyman</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4117-0279</contrib-id>
          <name>
            <surname>Shen</surname>
            <given-names>Yi</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Henriksson</surname>
            <given-names>Linda</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>KoÅ¡enina</surname>
            <given-names>Sara</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Dong</surname>
            <given-names>Min</given-names>
          </name>
          <address>
            <email>min.dong@childrens.harvard.edu</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Stenmark</surname>
            <given-names>PÃ¥l</given-names>
          </name>
          <address>
            <email>stenmark@dbb.su.se</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9377</institution-id><institution-id institution-id-type="GRID">grid.10548.38</institution-id><institution>Department of Biochemistry and Biophysics, </institution><institution>Stockholm University, </institution></institution-wrap>SE-106 91, Stockholm, Sweden </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">000000041936754X</institution-id><institution-id institution-id-type="GRID">grid.38142.3c</institution-id><institution>Department of Urology, Boston Childrenâs Hospital, Department of Microbiology and Immunobiology and Department of Surgery, </institution><institution>Harvard Medical School, </institution></institution-wrap>Boston, MA 02115 USA </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>14</day>
        <month>3</month>
        <year>2018</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>14</day>
        <month>3</month>
        <year>2018</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2018</year>
      </pub-date>
      <volume>8</volume>
      <elocation-id>4518</elocation-id>
      <history>
        <date date-type="received">
          <day>4</day>
          <month>12</month>
          <year>2017</year>
        </date>
        <date date-type="accepted">
          <day>28</day>
          <month>2</month>
          <year>2018</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Â© The Author(s) 2018</copyright-statement>
        <license license-type="OpenAccess">
          <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the articleâs Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the articleâs Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p id="Par1">Botulinum neurotoxins (BoNTs) are among the most potent toxins known and are also used to treat an increasing number of medical disorders. There are seven well-established serotypes (BoNT/A-G), which all act as zinc-dependent endopeptidases targeting specific members of the SNARE proteins required for synaptic vesicle exocytosis in neurons. A new toxin serotype, BoNT/X, was recently identified. It cleaves not only the canonical targets, vesicle associated membrane proteins (VAMP) 1/2/3 at a unique site, but also has the unique ability to cleave VAMP4/5 and Ykt6. Here we report the 1.35âÃ X-ray crystal structure of the light chain of BoNT/X (LC/X). LC/X shares the core fold common to all other BoNTs, demonstrating that LC/X is a bona fide member of BoNT-LCs. We found that access to the catalytic pocket of LC/X is more restricted, and the regions lining the catalytic pocket are not conserved compared to other BoNTs. Kinetic studies revealed that LC/X cleaves VAMP1 with a ten times higher efficiency than BoNT/B and the tetanus neurotoxin. The structural information provides a molecular basis to understand the convergence/divergence between BoNT/X and other BoNTs, to develop effective LC inhibitors, and to engineer new scientific tools and therapeutic toxins targeting distinct SNARE proteins in cells.</p>
      </abstract>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>Â© The Author(s) 2018</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p id="Par2">The clostridial neurotoxins are a family of bacterial toxins including seven BoNTs and the related tetanus neurotoxin (TeNT). They are the causative agents of the severe paralytic diseases, botulism and tetanus, respectively<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. BoNTs are the most poisonous protein toxins known to man, and yet have also been successfully used clinically to treat an ever-increasing number of disorders, such as strabismus, blepharospasm, cervical dystonia, overactive bladder, and pain<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>.</p>
      <p id="Par3">BoNTs consist of a light chain (LC, ~50âkDa) and a heavy chain (HC, ~100âkDa) linked by an inter-chain disulphide bridge<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. LC is a zinc-dependent endopeptidase, while HC is composed of two functional domains that are responsible for translocation (H<sub>N</sub>) and receptor binding (H<sub>C</sub>)<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. The toxin acts by first recognizing specific receptors at motor nerve terminals and enters neurons via receptor-mediated endocytosis. The acidic pH in endosomes then causes a conformational change of the toxin, resulting in translocation of LC across the endosomal membrane<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. LC targets one of three members of the SNARE family. BoNT/A, /C and /E cleave the peripheral membrane protein SNAP-25. BoNT/B, /D, /F, and /G cleave the vesicle-associated membrane protein VAMP1/2/3. BoNT/C can also cleave syntaxin 1<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. Cleavage of these SNARE proteins blocks fusion of the synaptic vesicles to the plasma membrane and thus inhibits neurotransmission release and causes paralysis.</p>
      <p id="Par4">BoNT-LCs are remarkably specific proteases and the three sets of neuronal SNARE proteins are the only known targets. Furthermore, each BoNT has its own unique cleavage site on their substrates. This specificity is due to extensive toxin-substrate interactions between regions (designated exosites) outside the conserved catalytic site in LCs and regions in the substrates beyond the cleavage site. In particular, a conserved motif in SNARE proteins known as the SNARE motif has been proposed to play crucial roles for recognition by toxins<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>. For instance, VAMP2 contains two copies of the SNARE motif (V1 and V2) and V1 is critical for efficient cleavage of VAMP2 by BoNT/D<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. Indeed, the co-crystal structure of LC/A in complex with SNAP-25 has defined two exosites (Î±- and Î²-) that interact with specific regions in SNAP-25<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>, and the crystal structure of LC/F in complex with peptides derived from VAMP2 also revealed three exosites that interact with VAMP2<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>.</p>
      <p id="Par5">The crystal structures of all BoNT-LCs have been resolved<sup><xref ref-type="bibr" rid="CR9">9</xref>â<xref ref-type="bibr" rid="CR16">16</xref></sup>. Despite the low degree of identity at the amino acid levels, all LCs display a highly conserved fold, presenting a compact globular aspect with mixed secondary structures of Î±-helices and Î²-strands. The catalytic pocket, which contains the HExxE zinc-dependent protease motif, showed similar composition and geometries across all BoNTs. It is likely that variations in the composition and placement of exosites determine which SNARE proteins can be cleaved, as well as the spatial location of the cleavage site on a SNARE protein. In addition, it has been shown that the residue located at the C-terminal side of the cleavage site (P1â position) in SNARE proteins is critical for efficient cleavage, and mutations at this site usually abolishes the cleavage by BoNTs. For instance, although BoNT/C cleaves both SNAP-25 and syntaxin 1, the P1â position in these two different substrates are conserved (Ala).</p>
      <p id="Par6">A new serotype of BoNT with unique substrate specificity was recently identified from the genome sequence of <italic>C</italic>. <italic>botulinum</italic> strain 111, and designated BoNT/X<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. BoNT/X cleaves VAMP1/2/3 between Arg66-Ala67 in VAMP2, which is distinct from the sites targeted by other BoNTs<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. Remarkably, BoNT/X is the first and only BoNT member that can cleave additional VAMP family proteins, VAMP4, VAMP5 and Ykt6. The cleavage site on VAMP4, VAMP5, and Ykt6 are at the homologous location as Arg66-Ala67 in VAMP2, but the residues at the cleavage site are different (Lys-Ser in VAMP4 and Ykt6, Arg-Ser in VAMP5). Thus, LC/X showed the unique capability to recognize a broad range of VAMPs and a remarkable degree of tolerance for residue changes at the cleavage site.</p>
      <p id="Par7">To understand the structural basis of LC/X action, here we resolved the high resolution X-ray crystal structure of LC/X and of its zinc-free, apo-form. LC/X presents common features with all other clostridial neurotoxins. However the detailed structural characterisation also highlights unique features that may confer LC/X with its unusual substrate specificity and enhanced cleavage efficiency.</p>
    </sec>
    <sec id="Sec2" sec-type="results">
      <title>Results and Discussion</title>
      <sec id="Sec3">
        <title>Crystal structure of LC/X</title>
        <p id="Par8">LC/X (residues 1â439) was recombinantly produced in <italic>E</italic>. <italic>coli</italic>, with an N-terminal poly-His(x6) tag. Two crystal forms were obtained under distinct crystallization conditions. In the first form, data from a single crystal were collected up to 1.35âÃ resolution (TableÂ <xref rid="Tab1" ref-type="table">1</xref>) and the structure of LC/X was solved using molecular replacement with LC/B as a template. Residues 1â413 were clearly defined, however no electron density was observed for the N-terminal tag and the C-terminal end (414â439), all in solvent-accessible areas. In the second crystal form, the metal chelator EDTA was included in the crystallisation condition, which resulted in the loss of the Zn<sup>2+</sup> ion from LC/X. Data from a single plate-like crystal were collected up to 2.4âÃ resolution and comprises residues 1â423 (TableÂ <xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Crystallographic statistics of the LC/X X-ray crystal structures.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>LC/X</th><th>Apo-LC/X</th></tr></thead><tbody><tr><td>PDB code</td><td>6F47</td><td>6F4E</td></tr><tr><td>Synchrotron source, Î»</td><td>Diamond I02, 0.979âÃ</td><td>SLS PXI, 1.00âÃ</td></tr><tr><td>Resolution (Ã)</td><td>1.35 (1.37â1.35)</td><td>2.4 (2.49â2.40)</td></tr><tr><td>Space group</td><td><italic>P2</italic><sub>1</sub>2<sub>1</sub>2<sub>1</sub></td><td><italic>P22</italic><sub>1</sub>2<sub>1</sub></td></tr><tr><td>Cell dimensions and angles</td><td>aâ=â58.3, bâ=â86.7, câ=â93.1âÃ; Î±â=âÎ²â=âÎ³â=â90Â°</td><td>aâ=â52.3, bâ=â94.5, câ=â113.0âÃ; Î±â=âÎ²â=âÎ³â=â90Â°</td></tr><tr><td>Total/Unique reflections</td><td>592,965<break/>98,954</td><td>176,299<break/>21,016</td></tr><tr><td>Completeness (%)<sup>a</sup></td><td>94.9 (64.8)</td><td>93.4 (88.9)</td></tr><tr><td>
<italic>R</italic>
<sub>merge</sub>
<sup>a,b</sup>
</td><td>0.083 (0.98)</td><td>0.123 (0.97)</td></tr><tr><td>
<italic>R</italic>
<sub>pim</sub>
<sup>a,c</sup>
</td><td>0.053 (0.74)</td><td>0.062 (0.52)</td></tr><tr><td>I/Ï(I)<sup>a</sup></td><td>9.2 (1.0)</td><td>8.9 (2.1)</td></tr><tr><td>CC<sub>1/2</sub><sup>d</sup></td><td>0.99 (0.42)</td><td>0.99 (0.69)</td></tr><tr><td>Multiplicity</td><td>6.0 (3.9)</td><td>8.4 (7.8)</td></tr><tr><td><italic>R</italic><sub><italic>cryst</italic></sub><sup><italic>e</italic></sup> (%)</td><td>14.3</td><td>21.5</td></tr><tr><td><italic>R</italic><sub>free</sub><sup>f</sup> (%)</td><td>17.6</td><td>26.0</td></tr><tr><td>Rmsd in bond lengths (Ã)</td><td>0.009</td><td>0.009</td></tr><tr><td>Rmsd in bond angles (Â°)</td><td>1.34</td><td>1.31</td></tr><tr><td colspan="3">
<bold>B- factor statistics (Ã</bold>
<sup><bold>2</bold></sup>
<bold>)</bold>
</td></tr><tr><td>Protein all atoms</td><td>20.3</td><td>53.6</td></tr><tr><td>Protein main chain atoms</td><td>18.4</td><td>51.4</td></tr><tr><td>Protein side chain atoms</td><td>22.2</td><td>55.7</td></tr><tr><td>Solvent atoms</td><td>36.0</td><td>46.8</td></tr><tr><td>Zn<sup>2+</sup> ion</td><td>18.2 (0.33 occupancy)</td><td>n/a</td></tr><tr><td colspan="3">
<bold>Ramachandran statistics (Molprobity)</bold>
</td></tr><tr><td>Favored</td><td>97.7%</td><td>97.1%</td></tr><tr><td>Outliers</td><td>0.0%</td><td>0.0%</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Values in parentheses refer to the highest resolution shell.</p><p><sup>b</sup><italic>R</italic><sub>merge</sub>â=âÎ£Î£<sub><italic>i</italic></sub>|<italic>I</italic><sub><italic>h</italic></sub> â <italic>I</italic><sub><italic>hi</italic></sub>|/Î£Î£<sub><italic>i</italic></sub><italic>I</italic><sub><italic>h</italic></sub>, where <italic>I</italic><sub><italic>h</italic></sub> is the mean intensity for reflection <italic>h</italic>.</p><p><sup>c</sup><italic>R</italic><sub>pim</sub>â=âÎ£<sub><italic>h</italic></sub> (1/<italic>n</italic><sub><italic>h</italic></sub> â 1) Î£<sub><italic>l</italic></sub> |<italic>I</italic><sub><italic>hl</italic></sub> â (<italic>I</italic><sub><italic>h</italic></sub>)|/Î£<sub><italic>h</italic></sub>Î£<sub><italic>l</italic></sub>(<italic>I</italic><sub><italic>h</italic></sub>).</p><p><sup>d</sup>Correlation coefficient between random half datasets.</p><p><sup>e</sup><italic>R</italic><sub>cryst</sub>â=âÎ£â<italic>F</italic><sub><italic>o</italic></sub>| â |<italic>F</italic><sub><italic>c</italic></sub>â/Î£|<italic>F</italic><sub><italic>o</italic></sub>|, where <italic>F</italic><sub><italic>o</italic></sub> and <italic>F</italic><sub><italic>c</italic></sub> are measured and calculated structure factors, respectively.</p><p><sup>f</sup><italic>R</italic><sub>free</sub>â=âÎ£â<italic>F</italic><sub><italic>o</italic></sub>| â |<italic>F</italic><sub><italic>c</italic></sub>|/Î£|<italic>F</italic><sub><italic>o</italic></sub>|, calculated from 5% of the reflections selected randomly and omitted during refinement.</p></table-wrap-foot></table-wrap></p>
        <p id="Par9">Despite only ~30% identity at the amino acid levels with other BoNTs, the overall structures of LC/X present a fold similar to other BoNTs with largely conserved secondary structural elements (Fig.Â <xref rid="Fig1" ref-type="fig">1</xref>). This high degree of similarity between LC/X and other BoNTs are reflected by the low root mean square deviations (rmsd) values between 2.3 and 2.9âÃ when compared to other BoNT-LCs (Fig.Â <xref rid="Fig1" ref-type="fig">1B</xref>, TableÂ <xref rid="Tab2" ref-type="table">2</xref>, Supplementary Fig.Â <xref rid="MOESM1" ref-type="media">S1</xref>). Interestingly, two of the BoNT-LCs that showed the highest sequence identity to LC/X (LC/B, 36%; LC/Te, 34%, for the structurally aligned residues) showed the least structural resemblance (rmsd of 2.8âÃ and 2.9âÃ, respectively). These differences between the structures rest mainly on the higher variations in the length and position of the flexible loop regions (Fig.Â <xref rid="Fig1" ref-type="fig">1C</xref>, Supplementary Fig.Â <xref rid="MOESM1" ref-type="media">S1</xref>). LC/D, which also cleaves VAMP1/2/3, is the closest structural homologue (rmsdâ=â2.3âÃ; <italic>Z</italic>-scoreâ=â47.1). However there was no general correlation between structural similarity and substrate preference, contrary to what was observed in the primary sequence pairwise alignments where the SNAP-cleaving BoNT have the lowest similarity to LC/X (TableÂ <xref rid="Tab2" ref-type="table">2</xref>). These data demonstrate that LC/X is a bona fide member of BoNT-LCs.<fig id="Fig1"><label>Figure 1</label><caption><p>Crystal structure of LC/X. (<bold>A</bold>) Ribbon representation of LC/X, the zinc ion (grey sphere) and other regions of interest are highlighted. (<bold>B</bold>) Comparison of LC/X with other VAMP-cleaving toxins. LC of serotypes B (sand, PDB 1EPW), D (yellow-green, PDB 2FPQ), F (gold, PDB 2A97), G (dark orange, PDB 1ZB7) and Te (light orange, PDB 1Z7H) were superimposed with LC/X (red).</p></caption><graphic xlink:href="41598_2018_22842_Fig1_HTML" id="d29e896"/></fig><table-wrap id="Tab2"><label>Table 2</label><caption><p>Pairwise comparison of LC/X with other clostridial neurotoxins using Dali<sup><xref ref-type="bibr" rid="CR37">37</xref></sup> and Needle (EMBOSS server).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="6">Dali</th><th colspan="3">Needle</th></tr><tr><th>PDB</th><th>rmsd</th><th>No. of aligned positions</th><th>No. of residues in matched structure</th><th>% Sequence identity of aligned positions</th><th><italic>Z</italic> score</th><th>% Sequence similarity</th><th>% Sequence identity</th><th>Score</th></tr></thead><tbody><tr><td>LC/D</td><td>2fpq</td><td>2.3</td><td>377</td><td>414</td><td>31</td><td>47.1</td><td>48</td><td>28</td><td>500</td></tr><tr><td>LC/F</td><td>2a97</td><td>2.3</td><td>365</td><td>392</td><td>33</td><td>46.4</td><td>47</td><td>30</td><td>520</td></tr><tr><td>LC/C</td><td>2qn0</td><td>2.3</td><td>384</td><td>429</td><td>31</td><td>45.8</td><td>47</td><td>31</td><td>507</td></tr><tr><td>LC/A</td><td>1xtf</td><td>2.4</td><td>389</td><td>427</td><td>32</td><td>45.4</td><td>44</td><td>29</td><td>465</td></tr><tr><td>LC/G</td><td>1zb7</td><td>2.4</td><td>367</td><td>414</td><td>36</td><td>44.0</td><td>49</td><td>33</td><td>546</td></tr><tr><td>LC/E</td><td>1t3a</td><td>2.5</td><td>370</td><td>400</td><td>30</td><td>47.0</td><td>45</td><td>29</td><td>434</td></tr><tr><td>LC/B</td><td>1f82</td><td>2.8</td><td>381</td><td>424</td><td>36</td><td>45.7</td><td>48</td><td>33</td><td>590</td></tr><tr><td>LC/Te</td><td>1z7h</td><td>2.9</td><td>384</td><td>426</td><td>34</td><td>46.5</td><td>48</td><td>31</td><td>549</td></tr></tbody></table></table-wrap></p>
        <p id="Par10">Notable structural differences between LC/X and other BoNT-LCs include the loop region 195â217 (Fig.Â <xref rid="Fig1" ref-type="fig">1A</xref>). It starts and ends with anti-parallel Î²-strands, which are longer than the corresponding regions in LC/B and orientate the rest of the unstructured loop towards the solvent accessible surface. While the majority of the LC fold usually remains identical no matter whether the LC is an isolated protein or within the context of the full-length toxin (holotoxin), similar loop regions in other BoNT-LCs have showed flexibility to accommodate interactions with BoNT-HC<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR18">18</xref></sup>, suggesting that the loop 195â217 might contribute to inter-domain interactions within BoNT/X. Indeed, superposition of LC/X with BoNT/B hints that loop 195â217 may interact with the central helices of the translocation domain (Fig.Â <xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Figure 2</label><caption><p>Superposition of LC/X with BoNT/B. LC/X was superposed to the LC of BoNT/B (PDB code 1EPW<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>) to illustrate the potential interaction with the translocation domain. LC/X is shown as a white surface while BoNT/B is showed as a blue ribbon (with its LC omitted from the structure for clarity). Residues flanking the groove of LC/X are highlighted in red.</p></caption><graphic xlink:href="41598_2018_22842_Fig2_HTML" id="d29e1235"/></fig></p>
        <p id="Par11">In addition to loop 195â217, a major difference was observed for one of the loops involved in SNAP-25 binding by LC/A known as loop-250<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>, which in LC/X makes a three-stranded Î²-sheet arrangement from residues 243 to 263 and extends away from the catalytic channel, in a structural feature unique to LC/X. Loop-250 was shown to take on a different conformation in LC/A where it went from an open configuration in its free form to a closed configuration upon substrate binding<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. Interestingly this loop corresponds to a random coil in other VAMP-cleaving LCs, with the exception of LC/F where it makes a Î²-hairpin, all have a length of 16 to 20 amino acids (Supplementary Fig.Â <xref rid="MOESM1" ref-type="media">S2</xref>). Superposition of LC/X with BoNT/B suggests that region 243â263 could interact with the translocation domain in full length BoNT/X (Fig.Â <xref rid="Fig2" ref-type="fig">2</xref>), in agreement with this loopâs apparent flexibility.</p>
      </sec>
      <sec id="Sec4">
        <title>Active site of LC/X and the structure of zinc-free LC/X</title>
        <p id="Par12">BoNTs are metallo-endopeptidases of the M27 family<sup><xref ref-type="bibr" rid="CR19">19</xref></sup> related to thermolysin, with a classical HExxH+E tetrahedral zinc-binding motif. The active site of LC/X has the overall conserved geometry shared with other BoNTs (Supplementary Fig.Â <xref rid="MOESM1" ref-type="media">S3</xref>). The Zn<sup>2+</sup> ion is coordinated by the triad His227, Glu228 and His 231 and a fourth coordination provided by a water molecule linked to Glu266 (Fig.Â <xref rid="Fig3" ref-type="fig">3A</xref>). The water molecule provides the nucleophile base required for the proteolytic activity. Additionally, the conserved Tyr363 is believed to stabilize catalytic intermediates<sup><xref ref-type="bibr" rid="CR15">15</xref></sup> and is within water-mediated hydrogen bond distance to the active site.<fig id="Fig3"><label>Figure 3</label><caption><p>Catalytic site of LC/X. Close-up view of the active site of LC/X in (<bold>A</bold>) the high-resolution structure of LC/X; and (<bold>B</bold>) the Apo-LC/X structure. Residues involved in proteolysis represented in sticks, zinc ion and water molecules as grey and red spheres, respectively. The electron density (2<italic>F</italic><sub><italic>O</italic></sub><italic>-F</italic><sub><italic>C</italic></sub>, contoured at 2Ï in both (A) and (B)) is shown as a blue mesh.</p></caption><graphic xlink:href="41598_2018_22842_Fig3_HTML" id="d29e1300"/></fig></p>
        <p id="Par13">In the second crystal form, which lacks Zn<sup>2+</sup>, the architecture of the active site did not present any rearrangement, demonstrating that the role of zinc is functional rather than structural (Fig.Â <xref rid="Fig3" ref-type="fig">3B</xref>). Only weak electron density could be observed for Glu266, which may be an indication of the side chain motility in absence of Zn<sup>2+</sup> coordination. Additionally, residues 411â421 present a unique beta hairpin configuration in the apo-LC/X structure. This region could not be modelled in the high-resolution structure due to weak electron density, which suggests that the LC/Xâs carboxy-terminal end is flexible.</p>
      </sec>
      <sec id="Sec5">
        <title>Access to the active site of LC/X is more restricted</title>
        <p id="Par14">Analysis of the surface accessible electrostatic potential highlighted the conserved negative electrostatic potential of the active site, deep inside an open cavity (Fig.Â <xref rid="Fig4" ref-type="fig">4</xref>). Interestingly, access to the catalytic pocket of LC/X appeared more restricted than in LC/B, and /F (Fig.Â <xref rid="Fig4" ref-type="fig">4</xref>). LC/D, the closest structural homologue of LC/X also presents a restrictive access to the catalytic site but contrast by its significantly more charged surface potential. The catalytic pocket of LC/X shows a narrow entrance flanked on one side by loop 57â60, composed of polar residues (Thr-Asn-Asn-Thr), and on the other side by the short 261â263 Î²-strand (Fig.Â <xref rid="Fig4" ref-type="fig">4A,B</xref>). Deeper within the cleft, residues 160â165 form a Î²-strand that borders the catalytic channel, with the <italic>S</italic> sub-pocket delineated by residues 235â242 (Fig.Â <xref rid="Fig4" ref-type="fig">4B</xref>). The <italic>S</italic> sub-pocket of LC/X is not particularly conserved compared to the other VAMP-cleaving toxins (Fig.Â <xref rid="Fig4" ref-type="fig">4C</xref>). These structural elements may be involved in substrate recognition and allow LC/X to cleave VAMPs at a specific and unique position<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. On the other end, the <italic>Sâ</italic> sub-pocket delimited by loops 192â195 and 360â365 is well conserved (Fig.Â <xref rid="Fig4" ref-type="fig">4C</xref>), and may help stabilise the interaction with the C-terminal end of the substrate upon binding. In particular, Arg360, which is strictly conserved across all clostridial neurotoxins, likely plays a key role in substrate interaction, similarly to its role described in BoNT/A<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. Consistently, mutations of Arg360 and Tyr363 in BoNT/X abrogated the toxinâs activity<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>.<fig id="Fig4"><label>Figure 4</label><caption><p>Surface potential and catalytic cleft of LC/X. (<bold>A</bold>) Left, ribbon representation of LC/X; right, surface representation of LC/X, /B, /D, /F and /Te with electrostatic potential calculated using the APBS tool in PyMol. (<bold>B</bold>) The substrate binding sites of LC/X highlighting the <italic>S</italic> an <italic>Sâ</italic> sub-pockets. (<bold>C</bold>) Sequence alignment of LC/X with other VAMP-cleaving toxins. Catalytic site residues are framed in red, residues of the <italic>S</italic> an <italic>Sâ</italic> sub-pockets are framed in blue and green, respectively. Stars denote amino acids involved in Zn<sup>2+</sup> coordination.</p></caption><graphic xlink:href="41598_2018_22842_Fig4_HTML" id="d29e1391"/></fig></p>
      </sec>
      <sec id="Sec6">
        <title>Comparison to LC/F-VAMP structure</title>
        <p id="Par15">Superposition of LC/X with the structure of LC/F bound to a VAMP-based peptide inhibitor<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> revealed a clear groove that extends from the catalytic site and all around LC/X (Fig.Â <xref rid="Fig5" ref-type="fig">5A</xref>). This structural feature is common to other BoNTs and is expected to be involved in extended substrate interactions. In addition, superposition of LC/X with the full length BoNT/B (Fig.Â <xref rid="Fig2" ref-type="fig">2</xref>) suggests that this groove also likely interacts with the so-called âbeltâ region of BoNT/X. The belt region surrounds the light chain in the full-length toxins and was shown to play a protective chaperone role in BoNT/A<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>.<fig id="Fig5"><label>Figure 5</label><caption><p>Comparison of LC/X to LC/F in complex with a VAMP-derived peptide inhibitor. LC/F in complex with a VAMP-derived inhibitor (PDB 3FIE) was superposed to LC/X. <bold>(A)</bold> The surface of LC/X is shown in white and the VAMP peptide is represented as a yellow ribbon (LC/F is not shown). Residues flanking the groove and potential exosites are highlighted in red. <bold>(B)</bold> Close-up view of the catalytic pocket highlighting the variations in the surrounding loops and exosites. LC/F is shown as a grey ribbon. <bold>(C)</bold> Close-up view of LC/X catalytic pocket and potential substrate binding sites. The bound VAMP inhibitor is shown as sticks (LC/F is not shown) and residues of LC/X potentially involved in substrate binding are presented as sticks.</p></caption><graphic xlink:href="41598_2018_22842_Fig5_HTML" id="d29e1428"/></fig></p>
        <p id="Par16">The comparison with the VAMP-bound LC/F also highlighted a significant difference at the loop defining exosites 1 and 2 in LC/F (residues 171â181)<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>, which corresponds to a much shorter three-residue long linker (171â173) in LC/X (Fig.Â <xref rid="Fig5" ref-type="fig">5B</xref>). This difference in exosites may explain their distinct cleavage sites on VAMP2. Assuming that VAMP binds to LC/X in the canonical direction, the LC/F peptide inhibitor is expected to fill the <italic>S</italic> subsite following a pattern where the C-terminal cysteine interacts with Zn<sup>2+</sup>. Based on this assumption, we further analysed the catalytic pocket to understand the variation in substrate specificity (Fig.Â <xref rid="Fig5" ref-type="fig">5C</xref>).</p>
        <p id="Par17">An unusual feature of LC/X is its tolerance for residue changes at the cleavage site: it cleaves VAMP1/2/3 between R-A, VAMP4 and Ykt6 between K-S, and VAMP5 between R-A (Supplementary Fig.Â <xref rid="MOESM1" ref-type="media">S4</xref>). We note that the residues at the P1 site (R and K) are positively charged. It is possible R/K may interact with the negatively charged or polar side chains of residues E265, S240 and N235 located within the S1 site. On the other side of the scissile bond, the P1â site (A or S) may be accommodated between Tyr363 and Asn165. At the P2â site, the negatively charged side chain of E or D may be involved in salt bridge formation with Arg350 further within the <italic>Sâ</italic> sub-pocket. Deeper within the catalytic cleft, positions P3â-P4â (A/V and L) of VAMP1/2/3 and Ykt6 are likely to make hydrophobic interactions towards Pro194, Phe195 and Pro219. We note that the P3â position in VAMP4/5 consists of polar residues (S and Q) that may come within hydrogen bonding distance of Lys193 and Lys365.</p>
      </sec>
      <sec id="Sec7">
        <title>LC/X has a higher cleavage efficiency than LC/B and LC/Te</title>
        <p id="Par18">As the substantial differences in the accessibility to the active site in LC/X may influence the efficiency of substrate cleavage, we next compared the cleavage kinetics between LC/X versus LC/B and LC/Te using a fluorescence resonance energy transfer (FRET) based toxin sensor. This sensor was based on the toxin reporter previously developed<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>, but replacing the original cyan fluorescent protein (CFP) and yellow fluorescent protein (YFP) with a new generation of fluorescent proteins, mRuby2 and Clover, as the FRET pair. We also replaced the linker between the two fluorescent proteins from the original VAMP2 to VAMP1, as VAMP1 is the dominant form expressed at peripheral motor nerve terminals<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. Cleavage of VAMP1 by toxins separates mRuby2 and Clover, thus reducing the FRET signal.</p>
        <p id="Par19">As shown in Fig.Â <xref rid="Fig6" ref-type="fig">6A</xref>, incubation of the FRET sensor (500ânM) with LC/X or /B (20ânM each) resulted in loss of FRET signal over time. The traces were fitted to a one-phase single exponential decay and the rate constants were determined as a measurement for activity. LC/X showed ~3â4 fold more activity than LC/B towards the VAMP-1 substrate, with a reaction rate of 0.07 and 0.02âmin<sup>â1</sup> for LC/X and LC/B, respectively (Fig.Â <xref rid="Fig6" ref-type="fig">6B</xref>, TableÂ <xref rid="Tab2" ref-type="table">2</xref>).<fig id="Fig6"><label>Figure 6</label><caption><p>LC/X showed a higher level of cleavage efficiency than LC/B and /Te. <bold>(A)</bold> FRET-based toxin sensor (500ânM) was incubated with LC/X or LX/B (20ânM each). FRET signals were recorded with a microplate reader. Traces represent triplicates of experiments. The data were fitted to a single exponential function (Error bars are SEM; inset are the residuals of the exponential fit). The fitting data were presented in Supplementary TableÂ <xref rid="MOESM1" ref-type="media">S1</xref>. <bold>(B)</bold> Relative activity of LC/B was normalized to the activity of LC/X based on their rate constants estimated from panel A. <bold>(C)</bold> FRET-based toxin sensor (7.5âÂµM) was incubated with LC/X (2.4ânM), LC/B (4.8ânM) or LC/Te (92ânM). The cleavage products (Y-axis, ÂµM) were estimated based on normalizing the FRET signal to the initial signal with 7.5âÂµM toxin sensor. The data were fitted to a 3-parameter equation to estimate the kinetic constants for each enzyme (inset: residuals of fit). The kinetics data were presented in TableÂ <xref rid="Tab3" ref-type="table">3</xref>.</p></caption><graphic xlink:href="41598_2018_22842_Fig6_HTML" id="d29e1505"/></fig></p>
        <p id="Par20">We next estimated cleavage kinetics by using lower levels of LCs. To generate a time-dependent enzyme progress curve, the sensor concentration was increased to 7.5âÂµM and enzyme concentrations were optimized based on estimated relative activities (2.4ânM LC/X, 4.8ânM LC/B, 92ânM LC/T). The cleavage product concentration was estimated based on normalizing the FRET signals to the signal at the initial sensor concentration (7.5âÂµM, Fig.Â <xref rid="Fig6" ref-type="fig">6C</xref>). The data were then fitted to estimate kinetic parameters, which are listed in TableÂ <xref rid="Tab3" ref-type="table">3</xref>. The estimated kinetic parameters for LC/B and LC/Te are similar to previously reported values<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>. The kinetic data confirmed that LC/X is substantially more efficient than LC/B (~10 fold) and LC/Te (~30 fold). This enhanced cleavage efficiency is largely due to a higher apparent turnover rate (270âmin<sup>â1</sup>) of LC/X towards VAMP1 than LC/B and LC/Te.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Lambert-Omega Function parameters (see Fig.Â <xref rid="Fig6" ref-type="fig">6C</xref>).</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>V (Î¼M/min)</th><th>Km (Î¼M)</th><th>Apparent rate (min<sup>â1</sup>)</th><th>Apparent efficiency (min<sup>â1</sup>/Î¼M)</th></tr></thead><tbody><tr><td>LC/X</td><td>0.65 (0.03)</td><td>4.3 (0.3)</td><td>271</td><td>63</td></tr><tr><td>LC/B</td><td>0.22 (0.01)</td><td>8.2 (0.8)</td><td>46</td><td>6</td></tr><tr><td>LC/Te</td><td>0.06 (0.01)</td><td>2.8 (0.8)</td><td>7</td><td>3</td></tr></tbody></table></table-wrap></p>
        <p id="Par21">In summary, the structural characteristics of LC/X highlighted several unique features such as the restricted access to the catalytic pocket and its surrounding loop regions. The location and composition of the potential VAMP-binding pockets and the groove surrounding LC/X have implications with regard to substrate binding and interaction of LC/X with the rest of the holotoxin. Key regions of the light chain likely exhibit a high level of flexibility to adapt from the tight interactions with the belt and translocation domain of BoNT/X, to a different conformation upon substrate recognition when the free LC reaches its intracellular neuronal target. Our studies also revealed that LC/X possessesâ&gt;â10-fold higher level of cleavage efficiency than LC/B and /Te, potentially due to the distinct features surrounding its active site. Future work on mutagenesis approaches and structural studies of LC/X in complex with VAMPs are required to pinpoint the exosites and fully understand substrate recognition. LC/X showed a high degree of tolerance for residues at the cleavage site and it has a higher level of activity than many BoNTs, it may serve as a promising candidate to engineer new toxin variants that can cleave SNARE proteins that currently cannot be targeted, such as VAMP7 and VAMP8, to provide novel scientific tools and therapeutic toxins.</p>
      </sec>
    </sec>
    <sec id="Sec8" sec-type="materials|methods">
      <title>Methods</title>
      <sec id="Sec9">
        <title>LC/X expression and purification</title>
        <p id="Par22">The gene for LC/X was synthesized and cloned into a pET/28a vector for expression in <italic>E</italic>.<italic>coli</italic> BL21 (DE3). Cultures were grown at 37âÂ°C and induction carried out at 18âÂ°C using 0.5âmM IPTG. Bacterial pellets were lysed with an Emulsiflex-C3 (Avestin, Germany) at 20âkPsi and the protein purified by affinity chromatography using a 5âml HisTrap HP column (GE Healthcare) followed by gel filtration with a 16/60 Superdex 200 column (GE Healthcare). The final sample was stored at 13.6âmg/ml in 20âmM HEPES pH7.5, 300âmM NaCl, 10% Glycerol and 2âmM TCEP.</p>
      </sec>
      <sec id="Sec10">
        <title>LC/X crystallisation and structure determination</title>
        <p id="Par23">Crystals of LC/X were obtained in two different forms. One presented prism-shaped crystals that grew within 24âh at 21âÂ°C using the hanging drop vapour-diffusion method where 1âÎ¼l of protein at 13.6âmg/ml was mixed with 1âÎ¼l of reservoir solution consisting of 19% v/v PEG1500, 0.1âM MMT pH 6.0. The second form presented plate-like crystals that grew within 2â3 days at 21âÂ°C with a similar set up and a reservoir solution consisting of 11% v/v PEG20000, 0.1âM MES pH 6.5, 10âmM EDTA. The crystals were transferred into a cryo-protectant solution consisting of their respective growing conditions supplemented with 25% v/v glycerol, and then frozen in liquid nitrogen for data collection. Diffraction data were collected at stations I02 of the Diamond Light Source (Didcot, UK), equipped with a PILATUS-6M detector (Dectris, Switzerland), and PXI of the Swiss Light Source (Villigen, Switzerland) equipped with a EIGER-16MX detector (Dectris, Switzerland). Complete datasets to 1.35âÃ and 2.4âÃ were collected from single crystals at 100âK. Raw data images were processed and scaled with Mosflm<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>, or XDS<sup><xref ref-type="bibr" rid="CR27">27</xref></sup> and AIMLESS<sup><xref ref-type="bibr" rid="CR28">28</xref></sup> using the CCP4 suite 7.0<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. The structure was solved using molecular replacement with the coordinates of a truncated LC/B (PDB code 1EPW<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>) as a search model in PHASER<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. The working models were refined using REFMAC5<sup><xref ref-type="bibr" rid="CR31">31</xref></sup> and manually adjusted with COOT<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. Water molecules were added with the help of ARP/wARP<sup><xref ref-type="bibr" rid="CR33">33</xref></sup> at positions where <italic>FoâFc</italic> electron density peaks exceeded 3Ï, and potential hydrogen bonds could be made. Validation was performed with MOLPROBITY<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>. Crystallographic data statistics are summarized in TableÂ <xref rid="Tab1" ref-type="table">1</xref>. All figures were drawn with PyMOL (SchrÃ¶dinger, LLC, New York).</p>
      </sec>
      <sec id="Sec11">
        <title>FRET-based toxin sensor</title>
        <p id="Par24">The FRET toxin sensor was constructed by fusing the Clover and mRuby2 fluorescent proteins to each ends of a human VAMP1 fragment (residues 34â87, GenBank No. CAA88760.1), and was cloned into pBAD/His-B vector using Gibson assembly. Electrocompetent <italic>E</italic>. <italic>coli</italic> strain DH10B was transformed with the plasmid. Transformed bacteria were cultured overnight on agar plates with 0.4âmg/ml ampicillin. A single colony was picked and grown overnight in 5âmL LB medium supplemented with 0.1âmg/ml ampicillin at 37âÂ°C. The 5âmL culture was then used to inoculate 500âmL of LB medium with ampicillin and grown to an optical density of 0.6. Protein expression was induced with the addition of 0.02% w/v arabinose and the culture was grown at 37âÂ°C for 4âh and then 20âÂ°C overnight. Bacteria were than harvested and the FRET sensor protein was purified from the supernatant by Ni-NTA affinity chromatography. The buffer of the purified protein was then exchanged to 10âmM Tris-HCl, 150âmM NaCl, pH 7.2 using a desalting column.</p>
      </sec>
      <sec id="Sec12">
        <title>Cleavage kinetics analysis</title>
        <p id="Par25">The cleavage assay was performed in a 50âÂµL volume at 37âÂ°C, with 500ânM FRET sensor in the assay buffer (50âmM HEPES, pH 7.1, 200âmM NaCl, 10âÂµM ZnCl<sub>2</sub>, 500âÂµg/mL BSA, 2âmM DTT). The FRET signals were detected using microplate reader in 96-well plates at 620/520ânm. In Fig.Â <xref rid="Fig6" ref-type="fig">6A</xref>, the data were fit to a one-phase single exponential decay using GraphPad Prism 4 software. In Fig.Â <xref rid="Fig6" ref-type="fig">6C</xref>, FRET sensor concentration was increased to 7.5âÂµM. The LC/X concentration was optimized experimentally and we selected 2.4ânM, which is sufficient to turn over all substrates within the assay time (~ 30âmin). Higher concentrations of LC/B (4.8ânM) and LC/T (92ânM) were used as these LCs showed lower activity compared to LC/X. Data were converted to a product accumulation plot by first transforming Y-axis (dividing 1 over the FRET signal), subtracting the baseline (the value from the control sample containing LC/X, FRET sensor, and EDTA), and then the concentration was deducted by normalizing to the value of the initial substrate concentration (7.5âÂµM). The data were then fitted to equation (<xref rid="Equ1" ref-type="">1</xref>) to estimate kinetic parameters<sup><xref ref-type="bibr" rid="CR35">35</xref>,<xref ref-type="bibr" rid="CR36">36</xref></sup>.<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$Y=W(x(t))=W\{\frac{[S]\circ }{KM}\cdot exp(\frac{[S]\circ -V\cdot t}{KM})\}$$\end{document}</tex-math><mml:math xmlns:mml="https://jats.nlm.nih.gov/ns/archiving/1.0/" id="M2" display="block"><mml:mi>Y</mml:mi><mml:mo>=</mml:mo><mml:mi>W</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mi>W</mml:mi><mml:mrow><mml:mo stretchy="true">{</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mi>S</mml:mi><mml:mo stretchy="false">]</mml:mo><mml:mo>â</mml:mo></mml:mrow><mml:mrow><mml:mi>K</mml:mi><mml:mi>M</mml:mi></mml:mrow></mml:mfrac><mml:mo>â</mml:mo><mml:mi>e</mml:mi><mml:mi>x</mml:mi><mml:mi>p</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mi>S</mml:mi><mml:mo stretchy="false">]</mml:mo><mml:mo>â</mml:mo><mml:mo>â</mml:mo><mml:mi>V</mml:mi><mml:mo>â</mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>K</mml:mi><mml:mi>M</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow><mml:mo stretchy="true">}</mml:mo></mml:mrow></mml:math><graphic xlink:href="41598_2018_22842_Article_Equ1.gif" position="anchor"/></alternatives></disp-formula>where W is the Lambert W(x) function approximation (2):<disp-formula id="Equ2"><label>2</label><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${W}^{w}(x)=ln\,(1+x)\cdot \{1-\frac{ln\,(1+ln\,(1+x))}{2\,+\,ln\,(1+x)}\}$$\end{document}</tex-math><mml:math xmlns:mml="https://jats.nlm.nih.gov/ns/archiving/1.0/" id="M4" display="block"><mml:msup><mml:mrow><mml:mi>W</mml:mi></mml:mrow><mml:mi>w</mml:mi></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mi>l</mml:mi><mml:mi>n</mml:mi><mml:mspace width=".25em"/><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>â</mml:mo><mml:mrow><mml:mo stretchy="true">{</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>â</mml:mo><mml:mfrac><mml:mrow><mml:mi>l</mml:mi><mml:mi>n</mml:mi><mml:mspace width=".25em"/><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>l</mml:mi><mml:mi>n</mml:mi><mml:mspace width=".25em"/><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mspace width=".25em"/><mml:mo>+</mml:mo><mml:mspace width=".25em"/><mml:mi>l</mml:mi><mml:mi>n</mml:mi><mml:mspace width=".25em"/><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac></mml:mrow><mml:mo stretchy="true">}</mml:mo></mml:mrow></mml:math><graphic xlink:href="41598_2018_22842_Article_Equ2.gif" position="anchor"/></alternatives></disp-formula></p>
        <p id="Par26">All analysis and fitting were performed in Synergy KaleidaGraph 4 or GraphPad Prism 4.</p>
      </sec>
      <sec id="Sec13">
        <title>Data availability</title>
        <p id="Par27">The atomic coordinates and structure factors (codes 6F47 and 6F4E) have been deposited in the Protein Data Bank (<ext-link ext-link-type="uri" xlink:href="http://wwpdb.org">http://wwpdb.org</ext-link>).</p>
      </sec>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Electronic supplementary material</title>
      <sec id="Sec14">
        <p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41598_2018_22842_MOESM1_ESM.pdf"><caption><p>Supplementary Information</p></caption></media></supplementary-material>
</p>
      </sec>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>Geoffrey Masuyer and Sicai Zhang contributed equally to this work.</p>
      </fn>
      <fn>
        <p>
          <bold>Electronic supplementary material</bold>
        </p>
        <p><bold>Supplementary information</bold> accompanies this paper at 10.1038/s41598-018-22842-4.</p>
      </fn>
      <fn>
        <p><bold>Publisher's note:</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>We thank the scientists at stations I02 of the Diamond Light Source (UK) and PXI of the Swiss Light Source (Switzerland) for their support during X-ray data collection. This study was partially supported by NIH grants (NS080833 and AI132387) to M.D.; the Swedish Research Council (2014â5667), the Wenner-Gren Foundation, and the Swedish Cancer Society (to P.S.). M.D. acknowledges support by the NIH-funded Harvard Digestive Disease Center (P30DK034854) and Boston Childrenâs Hospital Intellectual and Developmental Disabilities Research Center (P30HD18655). M.D. holds the Investigator in the Pathogenesis of Infectious Disease award from the Burroughs Wellcome Fund.</p>
    </ack>
    <notes notes-type="author-contribution">
      <title>Author Contributions</title>
      <p>L.H. and S.K. performed protein purification and crystallisation. G.M. carried out crystallography and analysed the data. S.Z. and S.B. carried out kinetic analysis of the toxin LC activity. Y.S. created the FRET sensor used in this study. G.M., P.S., and M.D. wrote the manuscript with input from all co-authors.</p>
    </notes>
    <notes notes-type="COI-statement">
      <sec id="FPar1">
        <title>Competing Interests</title>
        <p id="Par29">Boston Childrenâs Hospital has filed a provisional patent application (U.S. 62/360,239) for medical use of BoNT/X, with P.S., S.Z. and M.D. as inventors.</p>
      </sec>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schiavo</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Matteoli</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Montecucco</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Neurotoxins affecting neuroexocytosis</article-title>
          <source>Physiol. Rev.</source>
          <year>2000</year>
          <volume>80</volume>
          <fpage>717</fpage>
          <lpage>766</lpage>
          <pub-id pub-id-type="doi">10.1152/physrev.2000.80.2.717</pub-id>
          <?supplied-pmid 10747206?>
          <pub-id pub-id-type="pmid">10747206</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Clinical Uses of Botulinum Neurotoxins: Current Indications, Limitations and Future Developments</article-title>
          <source>Toxins</source>
          <year>2012</year>
          <volume>4</volume>
          <fpage>913</fpage>
          <lpage>939</lpage>
          <pub-id pub-id-type="doi">10.3390/toxins4100913</pub-id>
          <?supplied-pmid 23162705?>
          <pub-id pub-id-type="pmid">23162705</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Montal</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Botulinum neurotoxin: a marvel of protein design</article-title>
          <source>Annu. Rev. Biochem.</source>
          <year>2010</year>
          <volume>79</volume>
          <fpage>591</fpage>
          <lpage>617</lpage>
          <pub-id pub-id-type="doi">10.1146/annurev.biochem.051908.125345</pub-id>
          <?supplied-pmid 20233039?>
          <pub-id pub-id-type="pmid">20233039</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Swaminathan</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Molecular structures and functional relationships in clostridial neurotoxins</article-title>
          <source>FEBS J.</source>
          <year>2011</year>
          <volume>278</volume>
          <fpage>4467</fpage>
          <lpage>4485</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1742-4658.2011.08183.x</pub-id>
          <?supplied-pmid 21592305?>
          <pub-id pub-id-type="pmid">21592305</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rossetto</surname>
              <given-names>O</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>SNARE motif and neurotoxins</article-title>
          <source>Nature</source>
          <year>1994</year>
          <volume>372</volume>
          <fpage>415</fpage>
          <lpage>416</lpage>
          <pub-id pub-id-type="doi">10.1038/372415a0</pub-id>
          <?supplied-pmid 7984234?>
          <pub-id pub-id-type="pmid">7984234</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pellizzari</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mason</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Shone</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Montecucco</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>The interaction of synaptic vesicle-associated membrane protein/synaptobrevin with botulinum neurotoxins D and F</article-title>
          <source>FEBS Lett.</source>
          <year>1997</year>
          <volume>409</volume>
          <fpage>339</fpage>
          <lpage>342</lpage>
          <pub-id pub-id-type="doi">10.1016/S0014-5793(97)00482-1</pub-id>
          <?supplied-pmid 9224685?>
          <pub-id pub-id-type="pmid">9224685</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Breidenbach</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>BrÃ¼nger</surname>
              <given-names>AT</given-names>
            </name>
          </person-group>
          <article-title>Substrate recognition strategy for botulinum neurotoxin serotype A</article-title>
          <source>Nature</source>
          <year>2004</year>
          <volume>432</volume>
          <fpage>925</fpage>
          <lpage>929</lpage>
          <pub-id pub-id-type="doi">10.1038/nature03123</pub-id>
          <?supplied-pmid 15592454?>
          <pub-id pub-id-type="pmid">15592454</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Agarwal</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Stafford</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Swaminathan</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Mode of VAMP substrate recognition and inhibition of Clostridium botulinum neurotoxin F</article-title>
          <source>Nat. Struct. Mol. Biol.</source>
          <year>2009</year>
          <volume>16</volume>
          <fpage>789</fpage>
          <lpage>794</lpage>
          <pub-id pub-id-type="doi">10.1038/nsmb.1626</pub-id>
          <?supplied-pmid 19543288?>
          <pub-id pub-id-type="pmid">19543288</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Agarwal</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Eswaramoorthy</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kumaran</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Binz</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Swaminathan</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Structural analysis of botulinum neurotoxin type E catalytic domain and its mutant Glu212âââGln reveals the pivotal role of the Glu212 carboxylate in the catalytic pathway</article-title>
          <source>Biochemistry</source>
          <year>2004</year>
          <volume>43</volume>
          <fpage>6637</fpage>
          <lpage>6644</lpage>
          <pub-id pub-id-type="doi">10.1021/bi036278w</pub-id>
          <?supplied-pmid 15157097?>
          <pub-id pub-id-type="pmid">15157097</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Agarwal</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Binz</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Swaminathan</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Structural analysis of botulinum neurotoxin serotype F light chain: implications on substrate binding and inhibitor design</article-title>
          <source>Biochemistry</source>
          <year>2005</year>
          <volume>44</volume>
          <fpage>11758</fpage>
          <lpage>11765</lpage>
          <pub-id pub-id-type="doi">10.1021/bi0510072</pub-id>
          <?supplied-pmid 16128577?>
          <pub-id pub-id-type="pmid">16128577</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arndt</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Bi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Stevens</surname>
              <given-names>RC</given-names>
            </name>
          </person-group>
          <article-title>Crystal structure of botulinum neurotoxin type G light chain: serotype divergence in substrate recognition</article-title>
          <source>Biochemistry</source>
          <year>2005</year>
          <volume>44</volume>
          <fpage>9574</fpage>
          <lpage>9580</lpage>
          <pub-id pub-id-type="doi">10.1021/bi0505924</pub-id>
          <?supplied-pmid 16008342?>
          <pub-id pub-id-type="pmid">16008342</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arndt</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Chai</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Christian</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Stevens</surname>
              <given-names>RC</given-names>
            </name>
          </person-group>
          <article-title>Structure of botulinum neurotoxin type D light chain at 1.65Ã resolution: repercussions for VAMP-2 substrate specificity</article-title>
          <source>Biochemistry</source>
          <year>2006</year>
          <volume>45</volume>
          <fpage>3255</fpage>
          <lpage>3262</lpage>
          <pub-id pub-id-type="doi">10.1021/bi052518r</pub-id>
          <?supplied-pmid 16519520?>
          <pub-id pub-id-type="pmid">16519520</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Breidenbach</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>BrÃ¼nger</surname>
              <given-names>AT</given-names>
            </name>
          </person-group>
          <article-title>2.3Ã crystal structure of tetanus neurotoxin light chain</article-title>
          <source>Biochemistry</source>
          <year>2005</year>
          <volume>44</volume>
          <fpage>7450</fpage>
          <lpage>7457</lpage>
          <pub-id pub-id-type="doi">10.1021/bi050262j</pub-id>
          <?supplied-pmid 15895988?>
          <pub-id pub-id-type="pmid">15895988</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jin</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Structural and biochemical studies of botulinum neurotoxin serotype C1 light chain protease: implications for dual substrate specificity</article-title>
          <source>Biochemistry</source>
          <year>2007</year>
          <volume>46</volume>
          <fpage>10685</fpage>
          <lpage>10693</lpage>
          <pub-id pub-id-type="doi">10.1021/bi701162d</pub-id>
          <?supplied-pmid 17718519?>
          <pub-id pub-id-type="pmid">17718519</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Segelke</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Knapp</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kadkhodayan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Balhorn</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Rupp</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Crystal structure of Clostridium botulinum neurotoxin protease in a product-bound state: evidence for noncanonical zinc protease activity</article-title>
          <source>Proc. Natl. Acad. Sci. USA</source>
          <year>2004</year>
          <volume>101</volume>
          <fpage>6888</fpage>
          <lpage>6893</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.0400584101</pub-id>
          <?supplied-pmid 15107500?>
          <pub-id pub-id-type="pmid">15107500</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Swaminathan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Eswaramoorthy</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B</article-title>
          <source>Nat. Struct. Biol.</source>
          <year>2000</year>
          <volume>7</volume>
          <fpage>693</fpage>
          <lpage>699</lpage>
          <pub-id pub-id-type="doi">10.1038/78005</pub-id>
          <?supplied-pmid 10932256?>
          <pub-id pub-id-type="pmid">10932256</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Identification and characterization of a novel botulinum neurotoxin</article-title>
          <source>Nat. Commun.</source>
          <year>2017</year>
          <volume>8</volume>
          <fpage>14130</fpage>
          <pub-id pub-id-type="doi">10.1038/ncomms14130</pub-id>
          <?supplied-pmid 28770820?>
          <pub-id pub-id-type="pmid">28770820</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Masuyer</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Davies</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Chaddock</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Acharya</surname>
              <given-names>KR</given-names>
            </name>
          </person-group>
          <article-title>Structural analysis of Clostridium botulinum neurotoxin type D as a platform for the development of targeted secretion inhibitors</article-title>
          <source>Sci. Rep.</source>
          <year>2015</year>
          <volume>5</volume>
          <fpage>13397</fpage>
          <pub-id pub-id-type="doi">10.1038/srep13397</pub-id>
          <?supplied-pmid 26324071?>
          <pub-id pub-id-type="pmid">26324071</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rawlings</surname>
              <given-names>ND</given-names>
            </name>
            <name>
              <surname>Waller</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Barrett</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Bateman</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>MEROPS: the database of proteolytic enzymes, their substrates and inhibitors</article-title>
          <source>Nucleic Acids Res.</source>
          <year>2014</year>
          <volume>42</volume>
          <fpage>D503</fpage>
          <lpage>509</lpage>
          <pub-id pub-id-type="doi">10.1093/nar/gkt953</pub-id>
          <?supplied-pmid 24157837?>
          <pub-id pub-id-type="pmid">24157837</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sikorra</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Henke</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Galli</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Blinz</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Substrate recognition mechanism of VAMP/synaptobrevin-cleaving clostridial neurotoxins</article-title>
          <source>J. Biol. Chem.</source>
          <year>2008</year>
          <volume>283</volume>
          <fpage>21145</fpage>
          <lpage>21152</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M800610200</pub-id>
          <?supplied-pmid 18511418?>
          <pub-id pub-id-type="pmid">18511418</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Binz</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Bade</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rummel</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kollewe</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Alves</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Arg(362) and Tyr(365) of the botulinum neurotoxin type a light chain are involved in transition state stabilization</article-title>
          <source>Biochemistry</source>
          <year>2002</year>
          <volume>41</volume>
          <fpage>1717</fpage>
          <lpage>1723</lpage>
          <pub-id pub-id-type="doi">10.1021/bi0157969</pub-id>
          <?supplied-pmid 11827515?>
          <pub-id pub-id-type="pmid">11827515</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>BrÃ¼nger</surname>
              <given-names>AT</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Botulinum neurotoxin heavy chain belt as an intramolecular chaperone for the light chain</article-title>
          <source>PLoS Pathog.</source>
          <year>2007</year>
          <volume>3</volume>
          <fpage>1191</fpage>
          <lpage>1194</lpage>
          <pub-id pub-id-type="doi">10.1371/journal.ppat.0030113</pub-id>
          <?supplied-pmid 17907800?>
          <pub-id pub-id-type="pmid">17907800</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dong</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tepp</surname>
              <given-names>WH</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Chapman</surname>
              <given-names>ER</given-names>
            </name>
          </person-group>
          <article-title>Using fluorescent sensors to detect botulinum neurotoxin activity <italic>in vitro</italic> and in living cells</article-title>
          <source>Proc. Natl. Acad. Sci. USA</source>
          <year>2004</year>
          <volume>101</volume>
          <fpage>14701</fpage>
          <lpage>14706</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.0404107101</pub-id>
          <?supplied-pmid 15465919?>
          <pub-id pub-id-type="pmid">15465919</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peng</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Widespread sequence variations in VAMP1 across vertebrates suggest a potential selective pressure from botulinum neurotoxins</article-title>
          <source>PLoS Pathog.</source>
          <year>2014</year>
          <volume>10</volume>
          <fpage>e1004177</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.ppat.1004177</pub-id>
          <?supplied-pmid 25010769?>
          <pub-id pub-id-type="pmid">25010769</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hall</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Barbieri</surname>
              <given-names>JT</given-names>
            </name>
          </person-group>
          <article-title>Substrate recognition of VAMP-2 by botulinum neurotoxin B and tetanus neurotoxin</article-title>
          <source>J. Biol. Chem.</source>
          <year>2008</year>
          <volume>283</volume>
          <fpage>21153</fpage>
          <lpage>21159</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M800611200</pub-id>
          <?supplied-pmid 18511417?>
          <pub-id pub-id-type="pmid">18511417</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Battye</surname>
              <given-names>TG</given-names>
            </name>
            <name>
              <surname>Kontogiannis</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Powell</surname>
              <given-names>HR</given-names>
            </name>
            <name>
              <surname>Leslie</surname>
              <given-names>AG</given-names>
            </name>
          </person-group>
          <article-title>IMosflm: a new graphical interface for diffraction-image processing with MOSFLM</article-title>
          <source>Acta Cryst.</source>
          <year>2011</year>
          <volume>D67</volume>
          <fpage>271</fpage>
          <lpage>281</lpage>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <mixed-citation publication-type="other">Kabsch, W. 2010. XDS. <italic>Acta Cryst</italic>. D<bold>66</bold>, 125â132.</mixed-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Evans</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Scaling and assessment of data quality</article-title>
          <source>Acta Crystallogr.</source>
          <year>2006</year>
          <volume>D62</volume>
          <fpage>72</fpage>
          <lpage>82</lpage>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <mixed-citation publication-type="other">Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. <italic>Acta</italic>. <italic>Crystallogr</italic>. <bold>D50</bold>, 760â763 (1994).</mixed-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McCoy</surname>
              <given-names>AJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Phaser crystallographic software</article-title>
          <source>J. Appl. Crystallogr.</source>
          <year>2007</year>
          <volume>40</volume>
          <fpage>658</fpage>
          <lpage>674</lpage>
          <pub-id pub-id-type="doi">10.1107/S0021889807021206</pub-id>
          <?supplied-pmid 19461840?>
          <pub-id pub-id-type="pmid">19461840</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Murshudov</surname>
              <given-names>GN</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Refmac5 for the refinement of macromolecular crystal structures</article-title>
          <source>Acta Crystallogr.</source>
          <year>2011</year>
          <volume>D67</volume>
          <fpage>355</fpage>
          <lpage>367</lpage>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Emsley</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lohkamp</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Scott</surname>
              <given-names>WG</given-names>
            </name>
            <name>
              <surname>Cowtan</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Features and development of Coot</article-title>
          <source>Acta Crystallogr.</source>
          <year>2010</year>
          <volume>D66</volume>
          <fpage>486</fpage>
          <lpage>501</lpage>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <mixed-citation publication-type="other">Lamzin, V. S., Perrakis, A. &amp; Wilson, K. S. The ARP/WARP suite for automated construction and refinement of protein models. In <italic>Int</italic>. <italic>Tables for Crystallography</italic>. <italic>Vol</italic>. <italic>F: Crystallography of biological macromolecules</italic>. (eds Rossmann, M. G., Arnold, E.) 720â722 (Dordrecht, Kluwer Academic Publishers, 2001).</mixed-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>VB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>MolProbity: all-atom structure validation for macromolecular crystallography</article-title>
          <source>Acta Crystallogr.</source>
          <year>2010</year>
          <volume>D66</volume>
          <fpage>12</fpage>
          <lpage>21</lpage>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>GoliÄnik</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Exact and approximate solutions for the decades-old Michaelis-Menten equation: Progress-curve analysis through integrated rate equations</article-title>
          <source>Biochem. Mol. Biol. Educ.</source>
          <year>2011</year>
          <volume>39</volume>
          <fpage>117</fpage>
          <lpage>125</lpage>
          <pub-id pub-id-type="doi">10.1002/bmb.20479</pub-id>
          <?supplied-pmid 21445903?>
          <pub-id pub-id-type="pmid">21445903</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>GoliÄnik</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>On the Lambert W function and its utility in biochemical kinetics</article-title>
          <source>Biochem. Eng. J.</source>
          <year>2012</year>
          <volume>63</volume>
          <fpage>116</fpage>
          <lpage>123</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bej.2012.01.010</pub-id>
        </element-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hasegawa</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Holm</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Advances and pitfalls of protein structural alignment</article-title>
          <source>Curr. Opin. Struct. Biol.</source>
          <year>2009</year>
          <volume>19</volume>
          <fpage>341</fpage>
          <lpage>348</lpage>
          <pub-id pub-id-type="doi">10.1016/j.sbi.2009.04.003</pub-id>
          <?supplied-pmid 19481444?>
          <pub-id pub-id-type="pmid">19481444</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>